Skip to Content
Merck
CN

Sustaining Rapid Medicine Development

Lessons From A Pandemic

The Economist Impact Report: Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

Can drug developers and regulators create a sustainable culture that allows the biopharma industry to continue to work with the accelerated model adopted during the COVID-19 pandemic, or will industry burnout ensue?  

Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape

This report examines the following questions:

  • What will the biopharma regulatory science landscape look like in 2027?
  • What role will governments, regulators, and investors play in boosting the ecosystem for biopharma innovation, including sustainability targets?
  • Which therapeutic areas and technologies lend themselves to biopharma industry collaboration?
  • What will accelerate innovation cycles and regulatory approvals post-pandemic?
  • How will regulators deal with digitalization, artificial intelligence and machine learning in the drug approval process?
Download Full Report

The art of the possible: reimagining the biopharmaceutical supply chain

October 4th, 2022 10 am EDT/ 3pm BST

Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma

Meeta Gulyani

Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma

Mike Douma Vice President, Supply Chain AbbVie

Mike Douma

Vice President, Supply Chain AbbVie

Tacy Foster Partner McKinsey

Tacy Foster

Partner, McKinsey

Anne McDonald Pritchett Senior Vice President, Policy and Research PhRMA

Anne McDonald Pritchett

Senior Vice President, Policy and Research PhRMA

Alan Lovell Senior Manager, Health, Policy and Insights Economist Impact

Alan Lovell

Senior Manager, Health, Policy and Insights Economist Impact

Programmed by Economist Impact and sponsored by Merck, The art of the possible: reimagining the biopharmaceutical supply chain will examine what leaders in the biopharmaceutical supply chain must do to steer their businesses through a time of rapid change and ongoing disruption, and identify synergies and efficiencies to bring drugs to market more effectively.

Watch The Event
Related Services
Customer Collaboration Labs for Bioprocessing Optimization
Optimize your biomanufacturing at M Lab™ Collaboration Centers, where customers explore, learn and collaborate to solve their toughest bioprocess challenges.
Regulatory Focus Areas
We are on top of current trends and future quality and regulatory opportunities as well as challenges. We support our customers to navigate and comply with a highly complex set of global, regional, country, and industry-specific directives and regulations.
Emprove® Program – Two Decades of Easing Risk Management
Emprove® Program streamlines compliance with technical, regulatory, and supply information in Emprove® Dossiers, supporting risk assessment.
Pharma & Biopharma Startup Hub
Your new molecule or therapy begins its journey here. Find solutions and resources to navigate your path to successful drug discovery, development, and commercialization.
Sustainability
Long-term impact drives our sustainable success; shaping the future through products and technologies to solve global challenges.
Gene Therapy Manufacturing
Gene therapy innovation requires integrated manufacturing, testing, safety, and compliance expertise from experienced partners.
Sign In To Continue

To continue reading please sign in or create an account.

Don't Have An Account?